Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.31 |
| ▸ | DBH | P09172 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348683 | 0.82 | KMT2A (0.37) | ALDH1A1MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL9886154 | 0.82 | PTGS2 (0.42) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL18606046 | 0.80 | HTR2A (0.41) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL3488489 | 0.80 | ALDH1A1 (0.35) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL1940273 | 0.80 | MAPT (0.46) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL443415 | 0.78 | PDGFRB (0.39) | ALDH1A1MAPTLMNAGAAPDGFRB | |
| SCHEMBL24780295 | 0.77 | HTR2A (0.34) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL7494750 | 0.77 | CYP3A4 (0.49) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL22031396 | 0.77 | ALDH1A1 (0.33) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL17006092 | 0.77 | CYP1A2 (0.39) | ALDH1A1MEN1POLBHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175400-B1 | RENIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| CN-1147471-C | Renin inhibitors | - | 2004-04-28 | — | — | CN | disclosed |
| US-6673931-B2 | (4-(4-(3-(2-METHOXY-BENZYLOXY)-PROPOXY)-PHENYL)-5-(4-METHOXY -NAPHTHALEN-2-YLMETHOXY)-PIPERIDIN-3-YL)-METHANOL FOR EXAMPLE; USE TREATING RESTENOSIS, GLAUCOMA, CARDIAC AND KIDNEY INSUFFICIENCY | HOFFMAN-LA ROCHE INC. | 2004-01-06 | — | — | US | disclosed |
| US-20020087002-A1 | Naphthalenyl piperidines as renin inhibitors | NOVARTIS AG (CH) | 2002-07-04 | — | — | US | disclosed |
| CN-1349503-A | renin inhibitors | HOFFMANN LA ROCHE (CH) | 2002-05-15 | — | — | CN | disclosed |
| US-6376672-B1 | RESTENOSIS; VISION DEFECTS; CARDIOVASCULAR DISORDERS; KIDNEY DIEASES | HOFFMANN-LA ROCHE INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1175400-A1 | RENIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000064873-A1 | RENIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-11-02 | — | — | WO | disclosed |
| US-5444083-A | DOPAMINE AGONIST FOR TREATING OR PREVENTION OF HYPERTENSION OR HEART FAILURE | EISAI CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0381235-B1 | PYRROLIDINE COMPOUND AND PHARMACEUTICAL USE | Eisai Co., Ltd. (JP) | 1993-07-28 | — | — | EP | disclosed |
| CN-1044652-A | Pyrrolidine compound and its pharmaceutical use | EISAI CO LTD (JP) | 1990-08-15 | — | — | CN | disclosed |
| EP-0381235-A2 | Pyrrolidine compound and pharmaceutical use | Eisai Co., Ltd. (JP) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020087002-A1 | Naphthalenyl piperidines as renin inhibitors | REN, TNNI3, PTGIS | ALDH1A1 1055/4885MEN1 3818/4885POLB 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.